News & Updates

COVID-19 vaccine acceptance is high in Singapore, but there are still a reluctant few who prevent the nation from getting a higher immunization coverage against the infection.

The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.

For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.

Use of statins does not appear to be chemopreventive against colorectal cancer (CRC), and no significant association exists between total cholesterol level and CRC risk, a study has found. In addition, long-term statin use may increase the risk of colon cancer.

Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.

Antihypertensive therapy (AHT) may be used safely during the COVID-19 pandemic, as no evidence suggest that it can increase the risk of SARS-CoV-2 infection or death, according to a UK study. In addition, most classes of antihypertensives are negatively associated with COVID-19 diagnosis.